Neumora Therapeutics (NASDAQ:NMRA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 175.99% from the stock's current price.
A number of other analysts have also recently commented on NMRA. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. cut Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $23.40.
View Our Latest Stock Analysis on Neumora Therapeutics
Neumora Therapeutics Price Performance
Shares of NASDAQ:NMRA traded up $0.55 during trading on Monday, reaching $10.87. 790,841 shares of the company were exchanged, compared to its average volume of 745,176. The firm has a market capitalization of $1.76 billion, a PE ratio of -5.52 and a beta of 3.34. The business's fifty day simple moving average is $12.03 and its 200-day simple moving average is $11.52. Neumora Therapeutics has a 12-month low of $8.33 and a 12-month high of $21.00.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter in the previous year, the firm posted ($1.14) earnings per share. On average, sell-side analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.
Insider Activity
In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the transaction, the insider now directly owns 322,966 shares of the company's stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. This represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,400 shares of company stock valued at $686,361 in the last three months. 26.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Neumora Therapeutics
Several institutional investors have recently bought and sold shares of NMRA. SG Americas Securities LLC acquired a new stake in shares of Neumora Therapeutics in the second quarter worth approximately $566,000. Bank of New York Mellon Corp boosted its stake in Neumora Therapeutics by 474.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock worth $2,316,000 after purchasing an additional 194,559 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Neumora Therapeutics during the second quarter worth $166,000. Rhumbline Advisers raised its position in shares of Neumora Therapeutics by 488.3% in the second quarter. Rhumbline Advisers now owns 103,258 shares of the company's stock valued at $1,015,000 after buying an additional 85,706 shares during the last quarter. Finally, TD Asset Management Inc lifted its stake in shares of Neumora Therapeutics by 31.6% in the second quarter. TD Asset Management Inc now owns 144,994 shares of the company's stock worth $1,425,000 after buying an additional 34,800 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Articles
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
